Julia Vitarello, whose daughter Mila received a personalized medicine for her rare disease, is launching a new biotech company to scale up individualized therapies. This development matters as it could pave the way for more accessible and customized treatments, addressing gaps in current FDA guidance that previously led to the closure of her earlier venture, EveryONE Medicines. Watch for how this new initiative will navigate regulatory frameworks to bring personalized medicine to a broader patient population.
Read the full article at STAT News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

![[AINews] The Unreasonable Effectiveness of Closing the Loop](/_next/image?url=https%3A%2F%2Fmedia.nemati.ai%2Fmedia%2Fblog%2Fimages%2Farticles%2F600e22851bc7453b.webp&w=3840&q=75)



